Filtered By:
Management: National Institutes of Health (NIH)
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 769 results found since Jan 2013.
& #039;Black sheep & #039; of helper T cells may hold key to precision allergy treatment
A new Nature Immunology study led by University of Pittsburgh and National Institutes of Health researchers sheds light on how a rare type of helper T cell, called Th9, can drive allergic disease, suggesting new precision medicine approaches to treating allergies in patients with high levels of Th9.
Source: World Pharma News - May 3, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
US National Institutes of Health Prioritization of SARS-CoV-2 Variants
Emerg Infect Dis. 2023 Apr 13;29(5). doi: 10.3201/eid2905.221646. Online ahead of print.ABSTRACTSince late 2020, SARS-CoV-2 variants have regularly emerged with competitive and phenotypic differences from previously circulating strains, sometimes with the potential to escape from immunity produced by prior exposure and infection. The Early Detection group is one of the constituent groups of the US National Institutes of Health National Institute of Allergy and Infectious Diseases SARS-CoV-2 Assessment of Viral Evolution program. The group uses bioinformatic methods to monitor the emergence, spread, and potential phenotypic...
Source: Emerging Infectious Diseases - April 13, 2023 Category: Infectious Diseases Authors: Sam Turner Arghavan Alisoltani Debbie Bratt Liel Cohen-Lavi Bethany L Dearlove Christian Drosten Will M Fischer Ron A M Fouchier Ana Silvia Gonzalez-Reiche Lukasz Jaroszewski Zain Khalil Eric LeGresley Marc Johnson Terry C Jones Barbara M ühlemann David Source Type: research
Nanoparticle with mRNA appears to prevent, treat peanut allergies in mice
Key takeawaysPeanuts are one of the most common food allergens for children.UCLA scientists have developed a nanoparticle that delivers mRNA to liver cells in order to teach the immune system to tolerate peanut protein and alleviate allergies.In mice, the nanoparticle successfully dampened symptoms of serious allergy.Peanut allergies affect 1 in 50 children, and the most severe cases lead to a potentially deadly immune reaction called anaphylactic shock.Currently, there is only one approved treatment that reduces the severity of the allergic reaction, and it takes months to kick in. A group of UCLA immunologists is aiming ...
Source: UCLA Newsroom: Health Sciences - April 3, 2023 Category: Universities & Medical Training Source Type: news
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Case studies expose deadly risk of mpox to people with untreated HIV
In June 2022, a young man in his 30s severely sick with mpox, the viral disease formerly known as monkeypox, was admitted to the Salvador Zubirán National Institute of Health Sciences and Nutrition hospital in Mexico City. Tests showed the patient was also HIV-positive, which he had not known, and that his blood had few CD4 cells, critical immune cells that HIV attacks. The man’s immune system was so weak it could not keep mpox in check and painful lesions kept spreading across his body, eating away at, or necrotizing, the flesh, according to HIV researcher Brenda Crabtree Ramirez, who was on his care team. Then the vir...
Source: Science of Aging Knowledge Environment - February 21, 2023 Category: Geriatrics Source Type: research
Case studies expose deadly risk of mpox in people with untreated HIV
In June 2022, a young man in his 30s severely sick with mpox, the viral disease formerly known as monkeypox, was admitted to the Salvador Zubirán National Institute of Health Sciences and Nutrition hospital in Mexico City. Tests showed the patient was also HIV-positive, which he had not known, and that his blood had few CD4 cells, critical immune cells that HIV attacks. The man’s immune system was so weak it could not keep mpox in check and painful lesions kept spreading across his body, eating away at, or necrotizing, the flesh, according to HIV researcher Brenda Crabtree Ramirez, who was on his care team. Then the vir...
Source: ScienceNOW - February 21, 2023 Category: Science Source Type: news
Dedication
I dedicate this issue to Dr Anthony Fauci, who despite his long, dedicated, distinguished, and selfless public service as Director of the National Institute of Allergy and Infectious Diseases and Chief Medical Advisor to the President, has been subjected to public vilification because of his advocating public vaccination for the COVID-19 pandemic, an endorsement which has been proven to have saved millions of American lives. I am pleased to offer this dedication to celebrate his official retirement from the National Institutes of Health.
Source: Gastroenterology Clinics of North America - February 21, 2023 Category: Gastroenterology Authors: Mitchell S. Cappell Source Type: research
N.I.H. Did Not Properly Track a Group Studying Coronaviruses, Report Finds
An internal federal watchdog said that the health agency had not given adequate oversight to EcoHealth Alliance, which had been awarded $8 million in grants.
Source: NYT - January 26, 2023 Category: American Health Authors: Benjamin Mueller and Sheryl Gay Stolberg Tags: Coronavirus (2019-nCoV) United States Politics and Government Research Nonprofit Organizations Laboratories and Scientific Equipment EcoHealth Alliance National Institute of Allergy and Infectious Diseases National Institutes of Health Fau Source Type: news
Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial
LEIDEN, THE NETHERLANDS, (January 18, 2023) – The Janssen Pharmaceutical Companies of Johnson & Johnson, together with a consortium of global partners, today announced the results of an independent, scheduled data review of the Phase 3 Mosaico study (also known as HPX3002/HVTN706) of Janssen’s investigational HIV vaccine regimen. The study’s independent Data and Safety Monitoring Board (DSMB) determined that the regimen was not effective in preventing HIV infection compared to placebo among study participants. No safety issues with the vaccine regimen were identified.In light of the DSMB’s determination, the Mo...
Source: Johnson and Johnson - January 18, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Gastrointestinal and Hepatic Manifestations of Chronic Granulomatous Disease
J Allergy Clin Immunol Pract. 2023 Jan 13:S2213-2198(23)00050-8. doi: 10.1016/j.jaip.2022.12.039. Online ahead of print.ABSTRACTChronic granulomatous disease (CGD) is a rare inborn error of immunity, resulting from a defect in nicotinamide adenine dinucleotide phosphate (NADPH) oxidation and decreased production of phagocyte reactive oxygen species. The main clinical manifestations are recurrent infections and chronic inflammatory disorders. Current approaches to management include antimicrobial prophylaxis and control of inflammatory complications. Hematopoietic stem cell transplantation (HSCT) or gene therapy can provide...
Source: Cancer Control - January 16, 2023 Category: Cancer & Oncology Authors: Alexander H Yang Brigit Sullivan Christa S Zerbe Suk See De Ravin Andrew M Blakely Martha M Quezado Beatriz E Marciano Jamie Marko Alexander Ling David E Kleiner John I Gallin Harry L Malech Steven M Holland Theo Heller Source Type: research
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study
Lancet HIV. 2023 Jan 12:S2352-3018(22)00365-4. doi: 10.1016/S2352-3018(22)00365-4. Online ahead of print.ABSTRACTBACKGROUND: Long-acting injectable cabotegravir pre-exposure prophylaxis (PrEP) is recommended by WHO as an additional option for HIV prevention in sub-Saharan Africa, but there is concern that its introduction could lead to an increase in integrase-inhibitor resistance undermining treatment programmes that rely on dolutegravir. We aimed to project the health benefits and risks of cabotegravir-PrEP introduction in settings in sub-Saharan Africa.METHODS: With HIV Synthesis, an individual-based HIV model, we simul...
Source: Cancer Control - January 15, 2023 Category: Cancer & Oncology Authors: Jennifer Smith Loveleen Bansi-Matharu Valentina Cambiano Dobromir Dimitrov Anna Bershteyn David van de Vijver Katharine Kripke Paul Revill Marie-Claude Boily Gesine Meyer-Rath Isaac Taramusi Jens D Lundgren Joep J van Oosterhout Daniel Kuritzkes Robin Sch Source Type: research
Tiny implantable device designed by UCLA scientists helps kill cancer
Many solid tumors resist treatment in part by turning human biology against itself. Tumors surround themselves with extra white blood cells known as regulatory T cells, which call off the body ’s natural defenses against the disease.Strategies to treat cancer by deactivating these cells risk creating other serious problems. Since regulatory T cells play an important role in safeguarding healthy tissues, diminishing them throughout the body can lead to other immune cells mistakenly attacking these tissues and causing autoimmune conditions that damage the colon, liver, heart and other organs.Now, an interdisciplinary UCLA ...
Source: UCLA Newsroom: Health Sciences - January 4, 2023 Category: Universities & Medical Training Source Type: news
